Daclatasvir for the treatment of chronic hepatitis C virus infection

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.

Original languageEnglish (US)
Pages (from-to)277-288
Number of pages12
JournalDrugs of Today
Volume51
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Clinical Pharmacology
European Union
Therapeutics
Protease Inhibitors
Japan
Genotype
Safety
BMS-790052
Population
Proteins

Keywords

  • BMS-790052
  • Daclatasvir
  • HCV NS5A inhibitors
  • Hepatitis C

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Daclatasvir for the treatment of chronic hepatitis C virus infection. / Temesgen, Zelalem; Rizza, Stacey.

In: Drugs of Today, Vol. 51, No. 5, 01.05.2015, p. 277-288.

Research output: Contribution to journalArticle

@article{ea8d38cd72f14bfe8ac727012e420edf,
title = "Daclatasvir for the treatment of chronic hepatitis C virus infection",
abstract = "Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.",
keywords = "BMS-790052, Daclatasvir, HCV NS5A inhibitors, Hepatitis C",
author = "Zelalem Temesgen and Stacey Rizza",
year = "2015",
month = "5",
day = "1",
doi = "10.1358/dot.2015.51.5.2312449",
language = "English (US)",
volume = "51",
pages = "277--288",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Daclatasvir for the treatment of chronic hepatitis C virus infection

AU - Temesgen, Zelalem

AU - Rizza, Stacey

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.

AB - Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.

KW - BMS-790052

KW - Daclatasvir

KW - HCV NS5A inhibitors

KW - Hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=84938596314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938596314&partnerID=8YFLogxK

U2 - 10.1358/dot.2015.51.5.2312449

DO - 10.1358/dot.2015.51.5.2312449

M3 - Article

C2 - 26097901

AN - SCOPUS:84938596314

VL - 51

SP - 277

EP - 288

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -